Press Release

Astellas Announces Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Tokyo, October 28, 2016 – Astellas Pharma Inc. (TSE:4503, President and CEO: Yoshihiko Hatanaka, "the Company") announced that at the meeting of the Board of Directors held today, a resolution was adopted to acquire its own shares under Article 156 which is applicable in accordance with Article 165, paragraph 3 of the Companies Act.

Particulars

1. Reasons for the acquisition of own shares
   To improve capital efficiency and shareholder return.

2. Contents of acquisition

   (1) Class of shares to be acquired: Common stock of the Company

   (2) Total number of shares to be acquired: Up to 30 million shares
   (The percentage compared to the total number of shares outstanding: 1.41 %)

   (3) Aggregate amount of acquisition cost: Up to 50 billion yen

   (4) Period of acquisition: From October 31, 2016 to December 22, 2016

   (Reference)
   The status of treasury shares as of September 30, 2016:
   Total number of shares outstanding: 2,124,653,427 shares
   Number of treasury shares: 29,169,748 shares

######

About Astellas

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website at www.astellas.com/en.

Contacts for inquiries or additional information:

Astellas Pharma Inc.
Corporate Communications
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473